  As `` Immunotherapy age '' is coming , immune checkpoint inhibitors ( CPI) therapies have shown favorable clinical benefits and low toxicity profiles in patients with advanced non-small cell lung cancer ( NSCLC). While it is a pity that there is a little clear clinical trials evidence about immunotherapy among Asian population. Moreover , since there is an ethnic difference for targeted therapy , what about immunotherapy? Which factors may associate with ethnic differences from Caucasian population to Asiatic population? In this review , we supposed that the characteristics of the much higher proportion of EGFR mutation , hepatitis<pathogen> B<pathogen> virus<pathogen> infection and unexpected immune-related toxicity among Asian patients should be considered.